Moderna, Inc.

Equities

MRNA

US60770K1079

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 14:54:59 2024-07-16 EDT			5-day change	1st Jan Change
126.5 ^USD	+4.10%		+9.59%	+27.90%

07-15	Moderna Insider Sold Shares Worth $1,756,177, According to a Recent SEC Filing	MT
07-12	China approves CSPC Pharma's RSV vaccine for clinical trials	RE

U.S. FDA proposes to simplify COVID vaccine strategy

January 23, 2023 at 08:07 am

(Reuters) - The U.S. Food and Drug Administration on Monday proposed the use the latest updated shot available for disease, similar to the annual influenza immunization campaign, as it moves to simplify the COVID-19 vaccination strategy.

The proposal was outlined in its briefing documents which would be voted on by its panel of external advisers on Thursday.

(Reporting by Leroy Leo in Bengaluru; Editing by Shailesh Kuber)

Latest news about Moderna, Inc.

Moderna Insider Sold Shares Worth $1,756,177, According to a Recent SEC Filing	07-15	MT
China approves CSPC Pharma's RSV vaccine for clinical trials	07-11	RE
Flagship Pioneering Raises $3.6B for 'New Wave' of Health, AI Innovation	07-10	MT
Redburn Raises Moderna's Price Target to $117 From $116	07-10	MT
Bird flu response in Michigan sparks COVID-era worry on farms	07-10	RE
Moderna: partnership for mRNA vaccines in Japan	07-09	CF
Moderna Partners With Mitsubishi Tanabe Pharma to Promote Vaccines in Japan	07-09	MT
Moderna and Mitsubishi Tanabe Pharma Corporation Enter Joint Agreement to Promote Moderna?s Mrna Respiratory Vaccine Portfolio in Japan, Including Covid-19 Vaccines	07-08	CI
HilleVax to discontinue development of norovirus vaccine for infants; shares plummet	07-08	RE
Study finds Pfizer's RSV vaccine not tied to higher risk of pre-term births	07-08	RE
Moderna, Pfizer-BioNTech COVID-19 Vaccine Patent Legal Battle Gets Mixed UK Ruling	07-02	MT
Pfizer-BioNTech, Moderna Set to Appeal Mixed UK Ruling in COVID-19 Vaccine Patent Case	07-02	MT
Moderna: grant for influenza vaccine	07-02	CF
Moderna Receives $176 Million Award to Boost Development of mRNA-Based Pandemic Flu Vaccine	07-02	MT
UK court gives mixed ruling in Pfizer v Moderna COVID vaccine patents case	07-02	RE
Analysis-Scientists wary of bird flu pandemic 'unfolding in slow motion'	07-01	RE
Moderna, Inc.(NasdaqGS:MRNA) dropped from Russell 1000 Value-Defensive Index	06-30	CI
Moderna, Inc.(NasdaqGS:MRNA) dropped from Russell 1000 Defensive Index	06-30	CI
Moderna: positive CHMP opinion on RSV	06-28	CF
Wall Street Set to Open Higher Friday as Key Inflation Data Indicates Cooling Inflation	06-28	MT
Sector Update: Health Care Stocks Higher Pre-Bell Friday	06-28	MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday Ahead of Key Inflation Report	06-28	MT
Sector Update: Health Care	06-28	MT
Moderna Secures European Medicines Agency's Positive Opinion for mRESVIA	06-28	MT
European Medical Agency's Committee Backs Moderna's RSV Vaccine	06-28	MT

Chart Moderna, Inc.

Duration

Period

More charts

Company Profile

Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (95.7%) ; - revenues from grants (4%); - revenues from collaboration agreements (0.3%). At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development. Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).

Sector

Biotechnology & Medical Research

Calendar

2024-08-01 - Q2 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Moderna's RSV Vaccine Has 'Ample Opportunity' Despite Seasoned Competitors, Oppenheimer Says

June 12, 2024 at 03:38 pm

Moderna, Inc. prepares for the post-Covid era

March 25, 2024 at 10:24 am

Stéphane Bancel, CEO of Moderna: Restoring confidence in the vaccines sector

January 16, 2024 at 03:31 pm

More Strategies

Ratings for Moderna, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

121.5 USD

Average target price

145.9 USD

Spread / Average Target

+20.10%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+27.90%	46.56B
LONZA GROUP AG	+45.38%	41.67B
IQVIA HOLDINGS INC.	+0.24%	41.16B
ALNYLAM PHARMACEUTICALS, INC.	+32.66%	32.4B
ICON PUBLIC LIMITED COMPANY	+20.84%	28.18B
CELLTRION, INC.	-6.35%	28.1B
UNITED THERAPEUTICS CORPORATION	+48.90%	14.52B
MEDPACE HOLDINGS, INC.	+48.30%	13.74B
BIO-TECHNE CORPORATION	+3.15%	12.17B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-4.15%	11.14B

Other Biotechnology & Medical Research